news releases

21 April 2020

OncoImmune Starts Phase III Clinical Trial Testing the Power of Dampening Inflammation to Virus-induced Cellular Injury in Severe COVID-19 Patients

Category: News Releases

OncoImmune, Inc. initiated its Phase III clinical trial testing the safety and efficacy of CD24Fc in hospitalized COVID-19 patients (SAC-COVID) at the University of Maryland Baltimore Medical Center on April 20, 2020. The national trial will involve at least 10 medical centers throughout the nation.

Dr. Shyamasundaran Kottilil, Professor of Medicine, Director, Division of Clinical Care and Research at the Institute of Human Virology at the University of Maryland School of Medicine is the Principal Investigator of the trial and Dr. Joel Chua, Assistant Professor of Medicine, Division of Clinical Care and Research, Institute of Human Virology at the University of Maryland School of Medicine is the clinical principle investigator for the University of Maryland Medical Center. ClinSmart, LLC of Newton, Pennsylvania is the Clinical Research Organization contracted to manage the trial.

The new trial will test the impact of OncoImmune’s flagship product, CD24Fc, in dampening inflammation caused by virus-induced cellar injuries, which is likely a major underlying cause of cytokine storm, immune dysfunction and pneumonia observed in severe COVID-19 patients. A cohort of 230 subjects with severe clinical symptoms will be randomized and administered a single dose of CD24Fc (480 mg by IV infusion) or placebo and followed over a 28-day period to assess safety and efficacy in clinical improvement. As the drug has a novel mechanism of action, it will likely synergize with other drugs, including antiviral treatments such as chloroquine and Remdesivir, or other immune modulators targeting cytokines or their receptors. Therefore, the trial will accept patients undergoing, or intending to enroll in trials testing other experimental therapies.

“OncoImmune is grateful to Dr. Kottilil and the University of Maryland Baltimore for leading the clinical effort,” said Martin Devenport, the Chief-operating Officer of OncoImmune. “It took only 12 days from FDA approval to get the trial started and we could not have achieved this without the dedicated staff from the University and the CRO,” added Raymond Touomou, Vice President for Clinical Operations.

About Us

Based in Rockville, Maryland, OncoImmune is a
privately-held, clinical-stage biopharmaceutical
company that is actively engaged in the discovery
and development of biopharmaceuticals for the
treatment of cancer and autoimmune disease.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.